OTCs drive drugstore.com Q1 sales
This article was originally published in The Tan Sheet
Executive SummaryOver-the-counter net sales advanced 15% to $56.3 mil. during the first quarter, and order volumes for the segment grew by 15%, the online vendor announces April 25. OTCs are the "key drivers" of the business, making up 51% of revenues, the firm notes. The unit fueled 5.4% growth of net sales during the period to $109.8 mil. Drugstore.com reports a net loss of $3.8 mil. in Q1; however, the performance reflects a 29% improvement from the same period of 2006. Second quarter sales are anticipated to be in the range of $108 mil.-$110 mil., with a $3 mil.-$4 mil. net loss, the company says...
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.